The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis
Open accessAbstract
Atopic dermatitis ( AD ) is the most common inflammatory skin disease, but treatment options for moderate‐to‐severe disease are limited. Ustekinumab is an IL ‐12/ IL ‐23p40 antagonist that suppresses T h1, T h17 and T h22 activation, commonly used for psoriasis patients. We sought to assess efficacy and safety of ustekinumab in patients with moderate‐to‐severe AD . In this phase II , double‐blind, placebo‐controlled study, 33 patients with moderate‐to‐severe AD were randomly assigned to either ustekinumab (n=16) or placebo (n=17), with subsequent crossover at 16 weeks, and last dose at 32 weeks. Background therapy with mild topical steroids was allowed to promote retention. Study endpoints included clinical ( SCORAD 50) and biopsy‐based measures of tissue structure and inflammation, using protein and gene expression studies. The ustekinumab group achieved higher SCORAD 50 responses at 12, 16 (the primary endpoint) and 20 weeks compared to placebo, but the difference between groups was not significant. The AD molecular profile/transcriptome showed early robust gene modulation, with sustained further improvements until 32 weeks in the initial ustekinumab group. Distinct and more robust modulation of T h1, T h17 and T h22 but also T h2‐related AD genes was seen after 4 weeks of ustekinumab treatment (i.e. MMP 12, IL ‐22, IL ‐13, IFN ‐γ, elafin/ PI 3, CXCL 1 and CCL 17; P <.05). Epidermal responses ( K 16, terminal differentiation) showed faster (4 weeks) and long‐term regulation (32 weeks) from baseline in the ustekinumab group. No severe adverse events were observed. Ustekinumab had clear clinical and molecular effects, but clinical outcomes might have been obscured by a profound “placebo” effect, most likely due to background topical glucocorticosteroids and possibly insufficient dosing for AD .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Plasticity of CD4+ T Cell Lineage Differentiation
Zhou, L., Chong, M. M. W., & Littman, D. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.001 · Cited by 1,551 · cited 1×
“been assumed that the differentiation of naïve CD4 T-cells into lineages is an irreversible endpoint, recent data suggest a profound plasticity of CD4 T-cell differentiation in the context of human immune responses (29), substantiated by the finding that single human T-cell clones contributed to both Th17 and Th2 line…”
ResultNoda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Self-citationNograles, K. E., Zaba, L. C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., Ramon, M., Bergman, R., Krueger, J. G., & Guttman-Yassky, E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.041 · Cited by 627 · cited 1×
“Recent data suggest that AD is primarily immune-driven, like psoriasis, showing dense cellular infiltrates (1) and over-expression of certain cytokines in skin lesions (2).”
BackgroundSelf-citation
Cited by
The reactome pathway knowledgebase 2022
Gillespie, M., Jassal, B., Stephan, R., Milacic, M., Rothfels, K., Senff-Ribeiro, A., Griss, J., Sevilla, C., Matthews, L., Gong, C., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1028 · Cited by 2,339
Langan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Guttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Self-citation
Metadata
- Authors
- Khattri, S., Brunner, P. M., Garcet, S., Finney, R., Cohen, S. R., Oliva, M., Dutt, R., Fuentes‐Duculan, J., Zheng, X., Li, X., Bonifacio, K. M., Kunjravia, N., Coats, I., Cueto, I., Gilleaudeau, P., Sullivan‐Whalen, M., Suárez‐Fariñas, M., Krueger, J. G., & Guttman‐Yassky, E.
- Venue
- Experimental Dermatology
- Publisher
- Wiley
- Published
- 2016-08-09
- Volume
- 26
- Issue
- 1
- Pages
- 28-35
- ISSN
- 0906-6705 (ISSN-L)
- 1600-0625
- OpenAlex
- W2432916178
- Cited by
- 214
- References
- 4
- FWCI
- 31.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.